Pharma R&D Legend Stoffels To Take Helm At Galapagos
The troubled Belgian biotech has pulled off a major coup in hiring Paul Stoffels, the architect of J&J's R&D successes over the last decade, as its new CEO.
You may also be interested in...
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas’ digital shift plans.
Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.